Drug Trial Radar · NCT04257110
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Jul 28, 2020
Primary completion
Aug 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of BB-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, gastric/gastroesophageal junction cancer, bladder cancer and colon cancer, for exploring 1 or more RP2Ds or schedules for expanding/deepening the information/knowledge about clinical safety, clinical pharmacokinetics and anti-tumor activity.
Conditions
- Locally Advanced/Metastatic HER2 Positive Solid Tumors
Interventions
BB-1701Drug
BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events and serious adverse eventsTime frame: up to 2 years
- Number of subjects with dose limiting toxicity (DLT)Time frame: Cycle 1. Duration of each cycle is 21 days.
- MTDTime frame: Cycle 1. Duration of each cycle is 21 days.
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Sarah Cannon Research
Nashville, Tennessee
The Regents of NEXT Virginia, LLC
Fairfax, Virginia
Cancer Hospital Chinese Academy of Medical Science
Beijing, China
Sun Yat-sen Memorial Hospital
Guangzhou, China
The First Affiliated Hospital of Zhejiang University
Hangzhou, China
Sir Run Run Shaw Hospital - Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hanzhou, China
Linyi Cancer Hospital
Linyi, China
Hubei Cancer Hospital
Wuhan, China
Jiangsu Province Hospital
Nanjin, Jiangsu, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.